Table 1.
Baseline patient characteristics based on neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), systemic immune–inflammation index (SII), and systemic inflammation response index (SIRI).
| Cases a | NLR | PLR | SII | SIRI | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | Low | High | |||||||||||||
| ≤2.9 | >2.9 | ≤133.7 | >133.7 | ≤430.8 | >430.8 | ≤0.9 | >0.9 | |||||||||||||
| Demographics of Cases | All m
(n = 680) |
AA b
(n = 305) |
EA c
(n = 172) |
AA (n = 86) |
EA (n = 117) |
All (n = 679) |
AA b
(n = 212) |
EA c
(n = 144) |
AA c
(n = 178) |
EA c
(n = 145) |
All (n = 679) |
AA b
(n = 203) |
EA c
(n = 97) |
AA c
(n = 187) |
EA c
(n = 192) |
All (n = 678) |
AA b
(n = 190) |
EA c
(n = 70) |
AA c
(n = 200) |
EA c
(n = 217) |
| Age d | ||||||||||||||||||||
| Median (IQR e) in years | 63 (10) | 63 (9) | 63 (9) | 64 (11) | 65 (10) | 63 (10) | 63 (10) | 64 (10) | 64 (10) | 64 (11) | 63 (10) | 63 (10) | 63 (9) | 63 (10) | 64 (11) | 63 (10) | 63 (9) | 60 (9) | 63 (10) | 64 (11) |
| BMI | ||||||||||||||||||||
| Mean (SD f) in kg/m2 | 28.2 (5.0) | 28.3 (5.6) | 28.4 (4.1) | 27.1 (4.9) | 28.2 (4.9) | 28.2 (5.0) | 28.8 (5.6) | 28.8 (4.3) | 27.2 (5.3) | 27.9 (4.6) | 28.2 (5.0) | 28.4 (5.2) | 28.2 (3.9) | 27.7 (5.8) | 28.4 (4.7) | 28.2 (5.0) | 28.0 (5.0) | 27.1 (3.3) | 28.2 (6.0) | 28.7 (4.7) |
| Education, N (%) | ||||||||||||||||||||
| High school or less | 264 (39) | 137 (45) | 51 (30) | 36 (42) | 40 (34) | 263 (39) | 90 (42) | 47 (32) | 82 (46) | 44 (30) | 263 (39) | 93 (46) | 29 (30) | 79 (42) | 62 (32) | 263 (39) | 81 (43) | 18 (26) | 91 (46) | 73 (34) |
| Some college | 230 (34) | 117 (38) | 59 (34) | 27 (31) | 27 (23) | 230 (34) | 81 (38) | 48 (33) | 63 (35) | 38 (26) | 230 (34) | 76 (37) | 30 (31) | 68 (36) | 56 (29) | 230 (34) | 75 (39) | 19 (27) | 69 (34) | 66 (30) |
| College | 84 (12) | 25 (8) | 26 (15) | 10 (12) | 23 (20) | 84 (12) | 18 (8) | 24 (17) | 17 (10) | 25 (17) | 84 (12) | 18 (9) | 17 (18) | 17 (9) | 32 (17) | 84 (12) | 19 (10) | 13 (19) | 16 (8) | 36 (17) |
| Graduate | 47 (7) | 11 (4) | 15 (9) | 4 (5) | 17 (15) | 47 (7) | 9 (4) | 11 (8) | 6 (3) | 21 (14) | 47 (7) | 7 (3) | 6 (6) | 8 (4) | 26 (14) | 47 (7) | 5 (3) | 8 (11) | 10 (5) | 24 (11) |
| Did not provide | 55 (8) | 15 (5) | 21 (12) | 9 (10) | 10 (8) | 55 (8) | 14 (7) | 14 (10) | 10 (6) | 17 (12) | 55 (8) | 9 (4) | 15 (15) | 15 (8) | 16 (8) | 54 (8) | 10 (5) | 12 (17) | 14 (7) | 18 (8) |
| Baseline Health Factors | ||||||||||||||||||||
| Family history of prostate cancer g, N (%) | ||||||||||||||||||||
| No | 546 (80) | 255 (84) | 125 (73) | 68 (79) | 98 (84) | 545 (80) | 172 (81) | 109 (76) | 150 (84) | 114 (79) | 545 (80) | 169 (83) | 66 (68) | 153 (82) | 157 (82) | 545 (80) | 161 (85) | 46 (66) | 161 (81) | 176 (81) |
| Yes | 78 (11) | 33 (11) | 25 (14) | 9 (10.5) | 11 (9) | 78 (11) | 24 (11) | 21 (14) | 18 (10) | 15 (10) | 78 (12) | 23 (11) | 16 (16) | 19 (10) | 20 (10) | 78 (11) | 19 (10) | 12 (17) | 23 (11) | 24 (11) |
| Did not provide | 56 (8) | 17 (6) | 22 (13) | 9 (10.5) | 8 (7) | 56 (8) | 16 (8) | 14 (10) | 10 (6) | 16 (11) | 56 (8) | 11 (5) | 15 (15) | 15 (8) | 15 (8) | 55 (8) | 10 (5) | 12 (17) | 16 (8) | 17 (8) |
| Smoking status h, N (%) | ||||||||||||||||||||
| Current | 190 (28) | 106 (35) | 33 (19) | 30 (35) | 21 (18) | 189 (28) | 77 (36) | 32 (22) | 58 (33) | 22 (15) | 189 (28) | 66 (32) | 16 (16) | 69 (37) | 38 (20) | 190 (28) | 67 (35) | 12 (17) | 69 (34) | 42 (19) |
| Former | 254 (37) | 100 (33) | 68 (40) | 28 (33) | 58 (50) | 254 (37) | 67 (32) | 61 (42) | 61 (34) | 65 (45) | 254 (37) | 67 (33) | 42 (43) | 61 (33) | 84 (44) | 254 (37) | 62 (33) | 29 (41) | 66 (33) | 96 (44) |
| Never | 182 (27) | 83 (27) | 52 (30) | 19 (22) | 28 (24) | 182 (27) | 54 (25) | 39 (27) | 48 (27) | 41 (28) | 182 (27) | 60 (30) | 26 (27) | 42 (22) | 54 (28) | 181 (27) | 50 (26) | 18 (26) | 51 (26) | 62 (29) |
| Did not provide | 54 (8) | 16 (5) | 19 (11) | 9 (10) | 10 (8) | 54 (8) | 14 (7) | 12 (8) | 11 (6) | 17 (12) | 54 (8) | 10 (5) | 13 (13) | 15 (8) | 16 (8) | 53 (8) | 11 (6) | 11 (16) | 14 (7) | 17 (8) |
| Stage i, N (%) | ||||||||||||||||||||
| T1 | 117 (17) | 50 (16) | 37 (22) | 14 (16) | 16 (14) | 117 (17) | 39 (18) | 30 (21) | 25 (14) | 23 (16) | 117 (17) | 37 (18) | 22 (23) | 27 (14) | 31 (16) | 116 (17) | 35 (18) | 20 (28) | 29 (15) | 32 (15) |
| T2 | 461 (68) | 220 (72) | 108 (63) | 54 (63) | 79 (68) | 460 (68) | 147 (69) | 92 (64) | 126 (71) | 95 (65) | 460 (68) | 144 (71) | 57 (59) | 129 (69) | 130 (68) | 461 (68) | 131 (69) | 41 (59) | 143 (71) | 145 (67) |
| T3 | 54 (8) | 16 (5) | 22 (13) | 7 (8) | 9 (8) | 54 (8) | 17 (8) | 17 (12) | 6 (3) | 14 (10) | 54 (8) | 12 (6) | 13 (13) | 11 (6) | 18 (9) | 54 (8) | 15 (8) | 7 (10) | 8 (4) | 24 (11) |
| T4 | 44 (6) | 17 (6) | 4 (2) | 10 (12) | 13 (11) | 44 (6) | 6 (3) | 4 (3) | 21 (12) | 13 (9) | 44 (6) | 9 (4) | 4 (4) | 18 (10) | 13 (7) | 43 (6) | 8 (4) | 2 (3) | 18 (9) | 15 (7) |
| Missing | 4 (1) | 2 (1) | 1 (<1) | 1 (1) | 4 (1) | 3 (1) | 1 (1) | 4 (1) | 1 (<1) | 1 (1) | 2 (1) | 4 (1) | 1 (1) | 2 (1) | 1 (<1) | |||||
| Gleason score, N (%) | ||||||||||||||||||||
| ≤7 | 549 (81) | 251 (82) | 142 (83) | 64 (74) | 92 (79) | 548 (81) | 175 (83) | 116 (81) | 139 (78) | 118 (81) | 548 (81) | 171 (84) | 77 (79) | 143 (76) | 157 (82) | 548 (81) | 158 (83) | 62 (89) | 157 (78) | 170 (78) |
| >7 | 126 (18) | 51 (17) | 30 (17) | 20 (23) | 25 (21) | 126 (18) | 33 (16) | 28 (19) | 38 (21) | 27 (19) | 126 (18) | 31 (15) | 20 (21) | 40 (21) | 35 (18) | 125 (18) | 30 (16) | 8 (11) | 40 (20) | 47 (22) |
| Missing | 5 (1) | 3 (1) | 2 (2) | 5 (1) | 2 (2) | 1 (1) | 5 (1) | 1 (1) | 4 (2) | 5 (1) | 2 (1) | 3 (2) | ||||||||
| Disease aggressiveness, N (%) | ||||||||||||||||||||
| Nonaggressive disease j | 491 (72) | 230 (75) | 125 (73) | 58 (68) | 78 (67) | 490 (72) | 159 (75) | 104 (72) | 128 (72) | 99 (68) | 490 (72) | 158 (78) | 67 (69) | 129 (69) | 136 (71) | 490 (72) | 144 (76) | 55 (79) | 144 (72) | 146 (67) |
| Aggressive disease k | 185 (27) | 73 (24) | 46 (27) | 27 (31) | 39 (33) | 185 (27) | 50 (24) | 39 (27) | 50 (28) | 46 (32) | 185 (27) | 44 (22) | 29 (30) | 56 (30) | 56 (29) | 184 (27) | 45 (24) | 15 (21) | 54 (27) | 70 (32) |
| Missing | 4 (1) | 2 (1) | 1 (<1) | 1 (1) | 4 (1) | 3 (1) | 1 (1) | 4 (1) | 1 (1) | 1 (1) | 2 (1) | 4 (1) | 1 (1) | 2 (1) | 1 (1) | |||||
| PSA l | ||||||||||||||||||||
| Median (IQR) in ng/mL | 6.8 (7.0) | 7.0 (7.3) | 5.8 (4.4) | 7.5 (13.9) | 7.4 (9.5) | 6.8 (7.0) | 6.9 (6.5) | 6.1 (4.6) | 7.5 (10.9) | 6.8 (6.6) | 6.8 (7.0) | 6.8 (6.6) | 6 (4.25) | 7.4 (11.2) | 6.6 (7.3) | 6.8 (7.0) | 6.5 (6.7) | 5.8 (4.2) | 7.6 (11.1) | 6.7 (6.6) |
a Cases recruited within 2 years after disease diagnosis with an average interval between diagnosis and enrollment of 6.7 months; b AA: African American; c EA: European American; d Age at diagnosis; e IQR: Interquartile range; f SD: Standard deviation; g First-degree relative with prostate cancer; h Smoking status describes cigarette smoking; i Pathologically confirmed using American Joint Committee on Cancer (AJCC) 7th Edition; j Cases with pathologically confirmed T1 or T2 and Gleason score ≤ 7; k Cases with pathologically confirmed T3 or T4 or Gleason score > 7; l PSA: Prostate-specific antigen.